Cell proliferation in 3,800 node-negative breast cancers: Consistency over time of biological and clinical information provided by 3H-thymidine labelling index

Rosella Silvestrini, Maria Grazia Daidone, Antonella Luisi, Marinella Mastore, Monica Leutner, Bruno Salvadori

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

For breast cancer, many prognostic markers that initially appeared promising have failed to maintain their clinical predictive value. Few reports have analyzed the consistency over time of biological and clinical information provided by biomarkers. Tumour cell proliferation has acquired relevance as an indicator of prognosis and of response to treatment. Since its clinical role has been investigated for some decades, cell proliferation represents an ideal marker for an over-time validation. In 3,800 node-negative breast cancers recruited between 1972 and 1991, the consistency of information provided by the 3H-thymidine labelling index (TLI), in terms of basic relations with other clinico-pathological and biological variables and clinical predictivity, was evaluated using a combined analysis of results previously published by our group for distinct series of patients. Clinical predictivity was analyzed on a subset of 2,067 patients given local-regional therapy until relapse and followed for a median time from 6 to 10 years. Over the entire period TLI maintained a weak direct relation with tumour size and an inverse strong relation with steroid receptors. An increase in TLI was observed for tumours in post-menopausal patients up to the mid 1980s. During 3 different accrual periods (1972-1983; 1984-1987; 1988-1991), TLI was a consistent and independent predictor of relapse-free time, distant metastasis and overall survival, regardless of its consideration as a continuous variable or with a cutoff value of 3%. The reproducibility of our results over time provides support to the consistency of the methodology used and of the biological and clinical information obtained when using TLI as an indicator of breast cancer cell proliferation.

Original languageEnglish
Pages (from-to)122-127
Number of pages6
JournalInternational Journal of Cancer
Volume74
Issue number1
DOIs
Publication statusPublished - Feb 20 1997

Fingerprint

Thymidine
Cell Proliferation
Breast Neoplasms
Recurrence
Neoplasms
Steroid Receptors
Reproducibility of Results
Biomarkers
Neoplasm Metastasis
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cell proliferation in 3,800 node-negative breast cancers : Consistency over time of biological and clinical information provided by 3H-thymidine labelling index. / Silvestrini, Rosella; Daidone, Maria Grazia; Luisi, Antonella; Mastore, Marinella; Leutner, Monica; Salvadori, Bruno.

In: International Journal of Cancer, Vol. 74, No. 1, 20.02.1997, p. 122-127.

Research output: Contribution to journalArticle

Silvestrini, Rosella ; Daidone, Maria Grazia ; Luisi, Antonella ; Mastore, Marinella ; Leutner, Monica ; Salvadori, Bruno. / Cell proliferation in 3,800 node-negative breast cancers : Consistency over time of biological and clinical information provided by 3H-thymidine labelling index. In: International Journal of Cancer. 1997 ; Vol. 74, No. 1. pp. 122-127.
@article{4aef44c43cb341af8cdcc71e200a25e2,
title = "Cell proliferation in 3,800 node-negative breast cancers: Consistency over time of biological and clinical information provided by 3H-thymidine labelling index",
abstract = "For breast cancer, many prognostic markers that initially appeared promising have failed to maintain their clinical predictive value. Few reports have analyzed the consistency over time of biological and clinical information provided by biomarkers. Tumour cell proliferation has acquired relevance as an indicator of prognosis and of response to treatment. Since its clinical role has been investigated for some decades, cell proliferation represents an ideal marker for an over-time validation. In 3,800 node-negative breast cancers recruited between 1972 and 1991, the consistency of information provided by the 3H-thymidine labelling index (TLI), in terms of basic relations with other clinico-pathological and biological variables and clinical predictivity, was evaluated using a combined analysis of results previously published by our group for distinct series of patients. Clinical predictivity was analyzed on a subset of 2,067 patients given local-regional therapy until relapse and followed for a median time from 6 to 10 years. Over the entire period TLI maintained a weak direct relation with tumour size and an inverse strong relation with steroid receptors. An increase in TLI was observed for tumours in post-menopausal patients up to the mid 1980s. During 3 different accrual periods (1972-1983; 1984-1987; 1988-1991), TLI was a consistent and independent predictor of relapse-free time, distant metastasis and overall survival, regardless of its consideration as a continuous variable or with a cutoff value of 3{\%}. The reproducibility of our results over time provides support to the consistency of the methodology used and of the biological and clinical information obtained when using TLI as an indicator of breast cancer cell proliferation.",
author = "Rosella Silvestrini and Daidone, {Maria Grazia} and Antonella Luisi and Marinella Mastore and Monica Leutner and Bruno Salvadori",
year = "1997",
month = "2",
day = "20",
doi = "10.1002/(SICI)1097-0215(19970220)74:1<122::AID-IJC20>3.0.CO;2-G",
language = "English",
volume = "74",
pages = "122--127",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Cell proliferation in 3,800 node-negative breast cancers

T2 - Consistency over time of biological and clinical information provided by 3H-thymidine labelling index

AU - Silvestrini, Rosella

AU - Daidone, Maria Grazia

AU - Luisi, Antonella

AU - Mastore, Marinella

AU - Leutner, Monica

AU - Salvadori, Bruno

PY - 1997/2/20

Y1 - 1997/2/20

N2 - For breast cancer, many prognostic markers that initially appeared promising have failed to maintain their clinical predictive value. Few reports have analyzed the consistency over time of biological and clinical information provided by biomarkers. Tumour cell proliferation has acquired relevance as an indicator of prognosis and of response to treatment. Since its clinical role has been investigated for some decades, cell proliferation represents an ideal marker for an over-time validation. In 3,800 node-negative breast cancers recruited between 1972 and 1991, the consistency of information provided by the 3H-thymidine labelling index (TLI), in terms of basic relations with other clinico-pathological and biological variables and clinical predictivity, was evaluated using a combined analysis of results previously published by our group for distinct series of patients. Clinical predictivity was analyzed on a subset of 2,067 patients given local-regional therapy until relapse and followed for a median time from 6 to 10 years. Over the entire period TLI maintained a weak direct relation with tumour size and an inverse strong relation with steroid receptors. An increase in TLI was observed for tumours in post-menopausal patients up to the mid 1980s. During 3 different accrual periods (1972-1983; 1984-1987; 1988-1991), TLI was a consistent and independent predictor of relapse-free time, distant metastasis and overall survival, regardless of its consideration as a continuous variable or with a cutoff value of 3%. The reproducibility of our results over time provides support to the consistency of the methodology used and of the biological and clinical information obtained when using TLI as an indicator of breast cancer cell proliferation.

AB - For breast cancer, many prognostic markers that initially appeared promising have failed to maintain their clinical predictive value. Few reports have analyzed the consistency over time of biological and clinical information provided by biomarkers. Tumour cell proliferation has acquired relevance as an indicator of prognosis and of response to treatment. Since its clinical role has been investigated for some decades, cell proliferation represents an ideal marker for an over-time validation. In 3,800 node-negative breast cancers recruited between 1972 and 1991, the consistency of information provided by the 3H-thymidine labelling index (TLI), in terms of basic relations with other clinico-pathological and biological variables and clinical predictivity, was evaluated using a combined analysis of results previously published by our group for distinct series of patients. Clinical predictivity was analyzed on a subset of 2,067 patients given local-regional therapy until relapse and followed for a median time from 6 to 10 years. Over the entire period TLI maintained a weak direct relation with tumour size and an inverse strong relation with steroid receptors. An increase in TLI was observed for tumours in post-menopausal patients up to the mid 1980s. During 3 different accrual periods (1972-1983; 1984-1987; 1988-1991), TLI was a consistent and independent predictor of relapse-free time, distant metastasis and overall survival, regardless of its consideration as a continuous variable or with a cutoff value of 3%. The reproducibility of our results over time provides support to the consistency of the methodology used and of the biological and clinical information obtained when using TLI as an indicator of breast cancer cell proliferation.

UR - http://www.scopus.com/inward/record.url?scp=0030905685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030905685&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19970220)74:1<122::AID-IJC20>3.0.CO;2-G

DO - 10.1002/(SICI)1097-0215(19970220)74:1<122::AID-IJC20>3.0.CO;2-G

M3 - Article

C2 - 9036880

AN - SCOPUS:0030905685

VL - 74

SP - 122

EP - 127

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -